1. Home
  2. PVLA vs ASTH Comparison

PVLA vs ASTH Comparison

Compare PVLA & ASTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Palvella Therapeutics Inc.

PVLA

Palvella Therapeutics Inc.

HOLD

Current Price

$133.00

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo Astrana Health Inc.

ASTH

Astrana Health Inc.

HOLD

Current Price

$25.77

Market Cap

996.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
PVLA
ASTH
Founded
2015
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
996.1M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
PVLA
ASTH
Price
$133.00
$25.77
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
17
8
Target Price
$154.59
$38.88
AVG Volume (30 Days)
355.7K
473.1K
Earning Date
01-01-0001
06-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.33
Revenue
N/A
$519,907,752.00
Revenue This Year
N/A
$58.46
Revenue Next Year
N/A
$25.22
P/E Ratio
N/A
$61.70
Revenue Growth
N/A
45.90
52 Week Low
$18.23
$18.08
52 Week High
$151.18
$34.80

Technical Indicators

Market Signals
Indicator
PVLA
ASTH
Relative Strength Index (RSI) 68.31 66.14
Support Level $85.53 $23.37
Resistance Level N/A $28.49
Average True Range (ATR) 8.58 1.12
MACD 6.87 0.66
Stochastic Oscillator 73.74 91.78

Price Performance

Historical Comparison
PVLA
ASTH

About PVLA Palvella Therapeutics Inc.

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

About ASTH Astrana Health Inc.

Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.

Share on Social Networks: